DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the microbial dark matter. By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance. The new therapies discovered and developed by DEINOVE (antibiotics, antifungals, antivirals and antiparasitics) target superbugs (microbes that resist to one or several antimicrobials) that cause life-threatening infections which are now spreading at high speed.
This breakthrough approach gave birth to one of the World first specialized micro-biotechnology platforms and a unique collection of 10,000 rare strains and thousands of bacterial extracts. Nowadays, DEINOVE is conducting several development programs, of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infections, one of the World primary emergencies. The Company has also developed new bacterial micro-factories that address the other issue in the race against antimicrobial resistance: the industrial production of these rare and low concentrated compounds with often too complex chemical structures to be generated by chemical synthesis.
Based at the heart of the Euromédecine park in Montpellier, DEINOVE is listed on EURONEXT GROWTH® (ALDEI) since 2010. The Company has 50 employees and leans on a world class network of academic, technological, industrial and institutional partners.
This breakthrough approach gave birth to one of the World first specialized micro-biotechnology platforms and a unique collection of 10,000 rare strains and thousands of bacterial extracts. Nowadays, DEINOVE is conducting several development programs, of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infections, one of the World primary emergencies. The Company has also developed new bacterial micro-factories that address the other issue in the race against antimicrobial resistance: the industrial production of these rare and low concentrated compounds with often too complex chemical structures to be generated by chemical synthesis.
Based at the heart of the Euromédecine park in Montpellier, DEINOVE is listed on EURONEXT GROWTH® (ALDEI) since 2010. The Company has 50 employees and leans on a world class network of academic, technological, industrial and institutional partners.
Location: France, Occitania, Grabels
Employees: 51-200
Founded date: 2006
Investors 2
| Date | Name | Website |
| 20.05.2024 | Truffle Ca... | truffle.co... |
| - | TVM Capita... | tvm-lifesc... |
Mentions in press and media 8
| Date | Title | Description |
| 22.06.2022 | DEINOVE- Troisième convocation à une Assemblée générale extraordinaire le 5 juillet 2022 | DEINOVE- Troisième convocation à une Assemblée générale extraordinaire le 5 juillet 2022 DEINOVE (Euronext Growth Paris : ALDEI), société de biotechnologie française pionnière dans l’exploration et l'exploitation de la biodiversité bactérie... |
| 31.05.2022 | DEINOVE - Adoption of all the ordinary resolutions at the Shareholders’ Meeting of May 30, 2022 | DEINOVE - Adoption of all the ordinary resolutions at the Shareholders’ Meeting of May 30, 2022 The Extraordinary Shareholders’ Meeting will be convened on third notice on July 5, 2022 DEINOVE (Euronext Growth Paris: ALDEI), a French biotec... |
| 19.05.2022 | DEINOVE- Second convening to a Combined General Meeting on May 30, 2022 | DEINOVE- Second convening to a Combined General Meeting on May 30, 2022 DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global ch... |
| 07.04.2022 | The second part of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada | The second part of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada The extension of the clinical trial in Canada will add 5 new sites to those already active in the United States and ac... |
| 02.03.2022 | Thanks to the AGIR program, DEINOVE has become a unique French industrial biotech in the fight against antibiotic resistance | Thanks to the AGIR program, DEINOVE has become a unique French industrial biotech in the fight against antibiotic resistance The AGIR program, supported by the Investments for the Future Program, has allowed DEINOVE and the Charles Viollett... |
| 06.01.2022 | DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections | DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections The DSMB1 considered that the benefit/risk balance of antibiotic therapy with DNV3837 ... |
| 30.09.2021 | DEINOVE : presents its financial results and the advancement of its programs for the first half of 2021 | Phase II of the antibiotic candidate DNV3837 ongoing - end of the first part of the trial (DSMB) expected in Q4 2021 Strengthening of screening and analytical capacities with three complementary calls for projects won by DEINOVE Group net i... |
| 14.09.2021 | DEINOVE : Implementation of an agreement of notes convertible into new shares for a maximum nominal amount of 10M. Issuance of a first 500,000 tranche | This new agreement with European Select Growth Opportunities Fund enables the issuance of notes convertible into new shares for a maximum nominal amount of €10 m over a 24-month period. This new agreement gives DEINOVE additional financial ... |